title: CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer.
abstract: OBJECTIVE
  CD73 is a membrane associated 5'-ectonucleotidase that has been proposed as prognostic biomarker in various solid tumors. The aim of this study is to evaluate CD73 expression in a cohort of patients with primary bladder cancer in regard to its association with clinicopathological features and disease course.
  
  
  METHODS
  Tissue samples from 174 patients with a primary urothelial carcinoma were immunohistochemically assessed on a tissue microarray. Associations between CD73 expression and retrospectively obtained clinicopathological data were evaluated by contingency analysis. Survival analysis was performed to investigate the predictive value of CD73 within the subgroup of pTa and pT1 tumors in regard to progression-free survival (PFS).
  
  
  RESULTS
  High CD73 expression was found in 46 (26.4%) patients and was significantly associated with lower stage, lower grade, less adjacent carcinoma in situ and with lower Ki-67 proliferation index. High CD73 immunoreactivity in the subgroup of pTa and pT1 tumors (n = 158) was significantly associated with longer PFS (HR: 0.228; p = 0.047) in univariable Cox regression analysis.
  
  
  CONCLUSIONS
  High CD73 immunoreactivity was associated with favorable clinicopathological features. Furthermore, it predicts better outcome in the subgroup of pTa and pT1 tumors and may thus serve as additional tool for the selection of patients with favorable prognosis.
authors.affiliation: Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
authors.forename: Marian S
authors.initials: MS
authors.lastname: Wettstein
authors.affiliation: Institute of Surgical Pathology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
authors.forename: Lorenz
authors.initials: L
authors.lastname: Buser
authors.affiliation: Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
authors.forename: Thomas
authors.initials: T
authors.lastname: Hermanns
authors.affiliation: Institute of Pharmaceutical Sciences, ETH Zurich, 8093 Zurich, Switzerland.
authors.forename: Filip
authors.initials: F
authors.lastname: Roudnicky
authors.affiliation: Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
authors.forename: Daniel
authors.initials: D
authors.lastname: Eberli
authors.affiliation: Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
authors.forename: Philipp
authors.initials: P
authors.lastname: Baumeister
authors.affiliation: Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
authors.forename: Tullio
authors.initials: T
authors.lastname: Sulser
authors.affiliation: Institute of Surgical Pathology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
authors.forename: Peter
authors.initials: P
authors.lastname: Wild
authors.affiliation: Department of Urology, University Hospital, University of Zurich, 8091 Zurich, Switzerland.
authors.forename: Cédric
authors.initials: C
authors.lastname: Poyet
mesh_terms: D015720:5'-Nucleotidase / Q000235:genetics / Q000378:metabolism*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D002277:Carcinoma / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000473:pathology; D019459:Urothelium / Q000378:metabolism / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor; D015720:5'-Nucleotidase